USPTO serial 79434825
EPIGNOSTIX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- MORRIS, KRISTINA KLOIBER
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).
Need help with EPIGNOSTIX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable and recorded electronic data files featuring genetic and epigenetic data; Downloadable and recorded software for recording, storage, transmission or reproduction of genetic and epigenetic data content; downloadable and recorded application software for classification and diagnosis of downloadable and recorded digital DNA and epigenetic data and downloadable and recorded file management and database software for creating and managing image and data files representing classification and diagnosis of downloadable and recorded digital DNA and epigenetic data; downloadable and recorded database management software for genetic and epigenetic data; downloadable and recorded file server operating software for use in the field of genetic and epigenetic data; downloadable and recorded artificial intelligence software for classification and diagnosis of patient samples of blood or tissue using genetic and epigenetic data; downloadable and recorded artificial intelligence software for analyses of patient samples of blood or tissue using genetic and epigenetic data; downloadable and recorded artificial intelligence software for analyses, namely, analyses in the field of tumor diagnostics; downloadable and recorded artificial intelligence software for healthcare for classification and diagnosis of patient samples of blood or tissue using genetic and epigenetic data; downloadable and recorded artificial intelligence software for file sharing in the field of genetic and epigenetic data; downloadable and recorded software for data and file management and for databases for creating and managing image and data files of the classification result of patient samples of blood or tissue using genetic and epigenetic data; downloadable and recorded software for searching and retrieving information across a computer network in the field of genetic and epigenetic data; downloadable and recorded data software for monitoring health using genetic and epigenetic data; downloadable and recorded software for recording training data in the field of classification and diagnosis of patient samples of blood or tissue using genetic and epigenetic data; downloadable and recorded software for recording training data, namely, genetic and epigenetic training data in the field of oncology; downloadable and recorded software for recording training data, namely, genetic and epigenetic training data in the field of tumor diagnostics; downloadable and recorded data software for recording training data, namely, genetic and epigenetic training data in the field of genetics; downloadable and recorded software for recording training data, namely, genetic and epigenetic training data comprising nucleic acid data, DNA data and biochemical data; downloadable and recorded software for integrating of artificial intelligence and machine learning in the field of big data in the field of genetic and epigenetic data; downloadable and recorded software for healthcare, namely, for healthcare in the field of oncology for classification and diagnosis of patient samples of blood or tissue using genetic and epigenetic data; downloadable and recorded software for machine learning for creating data models classification and diagnosis of patient samples of blood or tissue using genetic and epigenetic data; downloadable and recorded software for machine learning for analysis of genetic and epigenetic data from patient samples of blood or tissue; downloadable and recorded software for machine learning for analysis purposes, namely, analysis in the field of tumor diagnostics using genetic and epigenetic data; downloadable and recorded interactive software based on artificial intelligence for classification and diagnosis of patient samples of blood or tissue using genetic and epigenetic data; downloadable and recorded software for integrating artificial intelligence and machine learning in the field of big data in the field of genetic and epigenetic data; downloadable software as a medical device (SaMD) for treating oncological diseases; downloadable software as a medical device(SaMD), namely, for the classification of tumors; downloadable software as a medical device(SaMD), namely, for the automated analysis of tumors; downloadable software as a medical device (SaMD), namely, for medical diagnostics for treating oncological diseases; downloadable software as a medical device(SaMD), namely, for tumor diagnostics; downloadable software as a medical device (SaMD), namely, in the field of oncology for classification and diagnosis of patient samples of blood or tissue | ACTIVE | — |
| 010 | Diagnostic, examination, and monitoring equipment for medical purposes, namely, equipment for DNA analysis, for analysis of genetic sequences, and for epigenetic analysis; diagnostic apparatus for medical purposes, namely, diagnostic genetic and epigenetic apparatus for medical purposes; diagnostic apparatus for medical purposes, namely, for diagnosing tumors; automatic analyzers for medical diagnostics, namely, for genetic and epigenetic medical diagnostics; automatic analyzers for medical diagnostics, namely, for automated analysis of tumors; automatic analyzers for medical diagnostics, namely, for automated analysis of patient blood, tissue and DNA samples; automatic analysis apparatus for medical diagnosis, namely, for automated analysis of DNA; diagnostic apparatus for medical purposes used in medical laboratories, namely, diagnostic genetic and epigenetic apparatus for medical purposes; apparatus for tumor diagnosis | ACTIVE | — |
| 042 | Scientific research for medical purposes in the area of cancerous diseases; software as a service (SaaS) services, namely, hosting software for use by others for classification and diagnosis of digital DNA or of epigenetic data and rental of software for use in classification and diagnosis of digital DNA or of epigenetic data ; software as a service (SaaS) services, namely, hosting software for use by others for classification and diagnosis of digital DNA or of epigenetic data in the field of oncology and rental of software for classification and diagnosis of digital DNA or of epigenetic data in the area of oncology; software as a service (SaaS) services, namely, hosting software for use by others for classification and diagnosis of digital DNA or of epigenetic data in the medical field and rental of software for classification and diagnosis of digital DNA or of epigenetic data in the medical field; software as a service (SaaS) services, namely, hosting software for use by others for tumor diagnosis and rental of software for tumor diagnosis; software as a service (SaaS) services, namely, hosting software for use by others for DNA analysis and rental of software for DNA analysis; software as a service (SaaS) services, namely, hosting software for use by others for the analysis of cancer and rental of software for the analysis of cancer; software development, programming and implementation; updating of memory bank software of computer systems; design and development of electronic databases software; development and testing of computing methods, algorithms and software; medical research in the field of oncology; testing, namely, product safety testing; quality control; testing, authentication, and quality control, namely quality control of hosting services, software as a service (SaaS), and software rental; quality control of hosting services, software as a service (SaaS), and software rental, namely of the aforementioned software as a service (SaaS); medical research laboratory services, namely, classification in the field of oncology; medical research laboratory services, namely, classification of tumors and cancer | ACTIVE | — |
| 044 | Providing cancer screening testing services; medical analysis services for the diagnosis of cancer; genetic testing for cancer risk for medical purposes; medical analysis services for cancer diagnosis and prognosis; medical analysis services for cancer diagnosis and prognosis, namely analysis services using software; performing RNA and DNA analyses for the diagnosis and prognosis of cancer; medical services in the field of oncology | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Heidelberg Epignostix GmbH
- Other trademarks owned by Heidelberg Epignostix GmbH
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named EPIGNOSTIX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 4, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 4, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 29, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 6, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 6, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 6, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 6, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 6, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 20, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 20, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 20, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 14, 2026 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Feb 19, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 30, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 30, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 30, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 29, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 27, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 17, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 17, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 16, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |